IOncology

As China’s flagship academic event in breast cancer at the start of each year, the Northern Breast Cancer Forum continues to bridge global scientific advances with localized clinical practice. From the SERENA-6 trial, which pioneers molecular monitoring for endocrine resistance, to the rapid rise of Trop-2–targeted ADCs and expanded access to PI3K/AKT/mTOR pathway inhibitors under national insurance coverage, the past year has witnessed profound shifts in breast cancer management.

Breast cancer has recently surpassed lung cancer as the most commonly diagnosed cancer among women worldwide. The status of regional lymph node involvement remains a key prognostic factor, directly influencing disease staging, treatment planning, and survival outcomes. While axillary lymph node dissection (ALND) has long been the standard for staging, it carries substantial morbidity. As modern breast surgery moves toward precision and minimally invasive approaches, sentinel lymph node biopsy (SLNB) has replaced ALND as the preferred axillary staging strategy, significantly reducing surgical trauma and complications.

Editor’s Note: Radical prostatectomy (RP) remains the primary surgical treatment for localized prostate cancer. However, a substantial proportion of patients experience biochemical recurrence (BCR) following surgery, which is closely associated…

Beijing Urologic Oncology Young Physicians Academic Exchange Meeting Editor’s Note: From January 10 to 11, 2026, the Beijing Urologic Oncology Young Physicians Academic Exchange Meeting was successfully held in Beijing.…

Editor’s Note From December 3 to 6, the Fifth Tianjin International Breast Cancer Conference was grandly held in Tianjin. The meeting was hosted by the Chinese Anti-Cancer Association and organized…

Editor’s Note The 2025 Yat-sen Breast Cancer Conference, held in conjunction with the 2025 CSCO BC Southern Forum, the Second National Conference on the Release of the Chinese Expert Consensus…

The 2025 Yat-sen Breast Cancer Conference, held in conjunction with the 2025 CSCO BC Southern Forum, the Second National Conference on the Release of the Chinese Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer, and the Fourth Yat-sen Breast Nursing Conference, took place in Guangzhou from December 26 to 27, 2025. The meeting focused on standardized breast cancer care, the evolution of cutting-edge treatment strategies, and precision management of young breast cancer patients, systematically presenting the latest advances and future directions in the field. During the conference, Oncology Frontier invited Professor Jing Yao from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, to interpret the newly released Chinese Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer (2025 Edition), and to analyze the characteristics, treatment strategies, and evolving screening approaches for young breast cancer patients in China.

Spotlight on SABCS, insights delivered live. The 48th San Antonio Breast Cancer Symposium (SABCS) was held from December 9 to 12, 2025, in San Antonio, USA, bringing together cutting-edge research findings and clinical insights from across the global breast cancer community. To efficiently convey the highlights of the meeting, this edition of Insight Broadcast invited Professor Junjie Li from Fudan University Shanghai Cancer Center as an on-site expert commentator. Focusing on neoadjuvant therapy for HER2-positive breast cancer, Professor Li provides an in-depth interpretation of the latest research advances on the use of biomarkers such as tumor-infiltrating lymphocytes (TILs) and circulating tumor DNA (ctDNA) to enable more precise patient selection and response prediction, while critically examining their potential, limitations, and future directions from a clinical perspective.

Spotlight on SABCS, insights delivered in real time. The 48th San Antonio Breast Cancer Symposium (SABCS) was held from December 9 to 12, 2025, in San Antonio, USA, bringing together cutting-edge research findings and clinical insights from the global breast cancer community. To efficiently convey the key messages of the meeting, this edition of Insight Broadcast invited Professor Jin Yang from the First Affiliated Hospital of Xi’an Jiaotong University as the on-site expert commentator. Drawing on two pivotal studies—ASCENT-07 and lidERA—Professor Yang interprets the latest advances and challenges in first-line treatment of advanced disease and adjuvant therapy in early-stage HR+/HER2− breast cancer, while exploring the evolving treatment paradigm and future directions.